Loading stock data…
Relmada Therapeutics (RLMD)
$4.25-0.18 (-4.06%)
Market ClosedLast close Sep 8
Relmada Therapeutics, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Relmada Therapeutics, Inc. in the Healthcare sector is trading at $4.25 with a market capitalization of $675M. Wall Street consensus targets $12.40 (5 analysts), implying a +191.8% move over the next 12 months. The stock is currently 47% below its 52-week high of $8.00, remaining 22.4% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: RSI 24 is oversold, raising the odds of a near-term bounce. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +191.8% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 24) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$19.46M↑ | -$20.33M↓ | -$10.33M↓ | -$10.22M↑ | -$18.22M |
| Net Income | -$19.05M↑ | -$19.87M↓ | -$10.09M↓ | -$9.87M↑ | -$17.56M |
Peer Comparison
JNJUNHPFE
Fundamentals
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clin...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$675.49M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-26.92%
Volume
Today's trading volume
1.70M
Recent News
After Plunging 18.5% in 4 Weeks, Here's Why the Trend Might Reverse for Relmada Therapeutics (RLMD)
Relmada Therapeutics (RLMD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Here's Why Relmada Therapeutics (RLMD) Is a Great 'Buy the Bottom' Stock Now
Relmada Therapeutics (RLMD) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Down 29.6% in 4 Weeks, Here's Why Relmada Therapeutics (RLMD) Looks Ripe for a Turnaround
Relmada Therapeutics (RLMD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Relmada Therapeutics Q2 Earnings Call Highlights
Relmada Therapeutics (NASDAQ:RLMD) said it is prioritizing manufacturing activities for NDV-01, its sustained-release intravesical formulation of gemcitabine and docetaxel for non-muscle invasive bladder cancer, as it targets an investigational new drug application filing by the end of 2026. Chief
Relmada Therapeutics Inc (RLMD) (Q2 2026) Earnings Call Highlights: Strong Phase 2 Data and FDA ...
Relmada Therapeutics Inc (RLMD) reports robust NDVO1 efficacy and a solid cash runway, but manufacturing delays push IND filing to end of 2026.